Guardant Health, Inc. (GH)
| Market Cap | 10.90B |
| Revenue (ttm) | 982.02M |
| Net Income (ttm) | -416.28M |
| Shares Out | 131.17M |
| EPS (ttm) | -3.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,554,468 |
| Open | 86.04 |
| Previous Close | 88.50 |
| Day's Range | 82.07 - 86.60 |
| 52-Week Range | 36.36 - 120.74 |
| Beta | 1.65 |
| Analysts | Strong Buy |
| Price Target | 119.79 (+44.12%) |
| Earnings Date | May 7, 2026 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc... [Read more]
Financial Performance
In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $119.79, which is an increase of 44.12% from the latest price.
News
Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2026 after market c...
Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that real-world evidence generated from Guardant's InfinityAI cont...
Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data
Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- ...
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 28 abstracts, incl...
Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership
PALO ALTO, Calif. & HONG KONG--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer detection (MCD) laborat...
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new national survey conducted on its behalf by The Harris...
Guardant Health Transcript: Barclays 28th Annual Global Healthcare Conference
Guardant360 and Reveal are driving growth through new clinical applications, including first-of-its-kind monitoring CDx and expanded MRD testing. Shield is rapidly closing the care gap in unscreened populations, supported by a growing sales force and strategic partnerships.
Guardant Health Transcript: Leerink Global Healthcare Conference 2026
A major partnership with Quest Diagnostics is set to expand Shield test access and drive physician engagement, while updated CRC guidelines and ongoing R&D are fueling growth across the portfolio. Revenue and margin improvements are expected through operational efficiencies, sales force expansion, and targeted DTC campaigns.
Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely acce...
Guardant Health Transcript: TD Cowen 46th Annual Health Care Conference
Exceptional growth in 2025 is expected to continue in 2026, driven by innovation across Guardant360, Reveal, and SHIELD, with new applications, expanded sales force, and key partnerships fueling adoption. FDA approval and ACS guideline endorsement are anticipated catalysts for further volume and reimbursement gains.
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Shield Across America, a historic coast-to-coast mobile scre...
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and cancer advocate Patrick Dempsey to increase...
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 23, 2026, the Compensation Committee of Guardant'...
Guardant Health Earnings Call Transcript: Q4 2025
Revenue grew 33% to $982M in 2025, driven by strong oncology and Shield screening adoption. 2026 guidance projects 27%–30% revenue growth, with continued investment in commercial expansion and new product launches.
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025. Fo...
Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open
Patient and Public Health Groups Invited to Apply for Up to 100 Shield Colorectal Cancer Blood Tests to Support Community Screening Events and Educational Outreach in March PALO ALTO, Calif., Feb. 12,...
Guardant Health to Participate in Upcoming Investor Conferences
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. B...
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
PALO ALTO, Calif. & ROCHESTER, Minn.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for C...
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2025...
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer
On Thursday, the U.S. Food and Drug Administration (FDA) approved Guardant Health Inc.'s (NASDAQ: GH) Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic c...
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guar...
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the Un...
Guardant Health Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted robust revenue and volume growth in oncology and screening, driven by smart platform innovation, new product launches, and strategic partnerships. Shield’s expansion into multi-cancer detection and strong financial position set the stage for continued growth and international expansion.
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended Decembe...
Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered...